Tan Xiaoyue, Li Yingjian, Liu Youhua
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
J Am Soc Nephrol. 2006 Dec;17(12):3382-93. doi: 10.1681/ASN.2006050520. Epub 2006 Nov 2.
Deficiency in vitamin D and its active metabolites is a pathologic feature of chronic kidney diseases. Despite that tubular epithelial cells are the major sites of active vitamin D synthesis, little is known about the role of vitamin D in maintaining the structural and functional integrity of tubular epithelium. This study investigated the effects of paricalcitol (19-nor-1,25-hydroxy-vitamin D(2)), a synthetic vitamin D analogue, on obstructive nephropathy, a model that is characterized by predominant tubulointerstitial lesions. Compared with vehicle controls, paricalcitol significantly attenuated renal interstitial fibrosis in mouse kidney after ureteral obstruction, as demonstrated by a reduced interstitial volume, decreased collagen deposition, and repressed mRNA expression of fibronectin and type I and type III collagens. Paricalcitol largely preserved E-cadherin and reduced alpha-smooth muscle actin expression in vivo. In addition, paricalcitol suppressed renal TGF-beta1 and its type I receptor expression, restored vitamin D receptor abundance, and inhibited cell proliferation and apoptosis after obstructive injury. In vitro, paricalcitol abolished TGF-beta1-mediated E-cadherin suppression and alpha-smooth muscle actin and fibronectin induction in tubular epithelial cells, underscoring its ability to block directly the epithelial to mesenchymal transition (EMT). It is interesting that paricalcitol almost completely suppressed renal induction of Snail, a critical transcription factor that is implicated in EMT programming. Furthermore, paricalcitol inhibited the TGF-beta1-mediated Snail induction in vitro, and ectopic expression of Snail repressed E-cadherin promoter activity and downregulated E-cadherin expression in tubular epithelial cells. These studies suggest that paricalcitol is able to ameliorate renal interstitial fibrosis in obstructive nephropathy, possibly by preserving tubular epithelial integrity through suppression of EMT.
维生素D及其活性代谢产物缺乏是慢性肾脏病的一个病理特征。尽管肾小管上皮细胞是活性维生素D合成的主要部位,但关于维生素D在维持肾小管上皮结构和功能完整性方面的作用却知之甚少。本研究调查了合成维生素D类似物帕立骨化醇(19-去甲-1,25-二羟基维生素D₂)对梗阻性肾病的影响,梗阻性肾病是以肾小管间质病变为主的模型。与载体对照组相比,帕立骨化醇显著减轻了输尿管梗阻后小鼠肾脏的肾间质纤维化,表现为间质体积减小、胶原沉积减少以及纤连蛋白、I型和III型胶原的mRNA表达受抑制。帕立骨化醇在体内很大程度上保留了E-钙黏蛋白并降低了α-平滑肌肌动蛋白的表达。此外,帕立骨化醇抑制了肾脏中转化生长因子β1及其I型受体的表达,恢复了维生素D受体的丰度,并抑制了梗阻性损伤后的细胞增殖和凋亡。在体外,帕立骨化醇消除了转化生长因子β1介导的肾小管上皮细胞中E-钙黏蛋白的抑制以及α-平滑肌肌动蛋白和纤连蛋白的诱导,突出了其直接阻断上皮-间质转化(EMT)的能力。有趣的是,帕立骨化醇几乎完全抑制了肾脏中Snail的诱导,Snail是一种与EMT编程有关的关键转录因子。此外,帕立骨化醇在体外抑制了转化生长因子β1介导的Snail诱导,并且Snail的异位表达抑制了E-钙黏蛋白启动子活性并下调了肾小管上皮细胞中E-钙黏蛋白的表达。这些研究表明,帕立骨化醇能够改善梗阻性肾病中的肾间质纤维化,可能是通过抑制EMT来维持肾小管上皮完整性。